Significant Efficacy of a Single Low Dose of Primaquine Compared to Stand-Alone Artemisinin Combination Therapy in Reducing Gametocyte Carriage in Cambodian Patients with Uncomplicated Multidrug-Resistant Plasmodium falciparum Malaria
Open Access
- 21 May 2020
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (6)
- https://doi.org/10.1128/aac.02108-19
Abstract
Since 2012, a single low dose of primaquine (SLDPQ; 0.25 mg/kg of body weight) with artemisinin-based combination therapies has been recommended as the first-line treatment of acute uncomplicated Plasmodium falciparum malaria to interrupt its transmission, especially in low-transmission settings of multidrug resistance, including artemisinin resistance. Policy makers in Cambodia have been reluctant to implement this recommendation due to primaquine safety concerns and a lack of data on its efficacy. In this randomized controlled trial, 109 Cambodians with acute uncomplicated P. falciparum malaria received dihydroartemisinin-piperaquine (DP) alone or combined with SLDPQ on the first treatment day. The transmission-blocking efficacy of SLDPQ was evaluated on days 0, 1, 2, 3, 7, 14, 21, and 28, and recrudescence by reverse transcriptase PCR (RT-PCR) (gametocyte prevalence) and membrane feeding assays with Anopheles minimus mosquitoes (gametocyte infectivity). Without the influence of recrudescent infections, DP-SLDPQ reduced gametocyte carriage 3-fold compared to that achieved with DP. Of 48 patients tested on day 0, only 3 patients were infectious to mosquitoes (similar to 6%). Posttreatment, three patients were infectious on day 14 (3.5%, 1/29) and on the 1st and 7th days of recrudescence (8.3%, 1/12 for each); this overall low infectivity precluded our ability to assess its transmission-blocking efficacy. Our study confirms the effective gametocyte clearance of SLDPQ when combined with DP in multidrug-resistant P. falciparum infections and the negative impact of recrudescent infections due to poor DP efficacy. Artesunate-mefloquine (ASMQ) has replaced DP, and ASMQ-SLDPQ has been deployed to treat all patients with symptomatic P. falciparum infections to further support the elimination of multidrug-resistant P. falciparum in Cambodia.Funding Information
- International Division Fellowship Pasteur Paris
- FEI 5% (12INI211)
- Rotary Club (GG1523934)
- Dedonder Clayton (EC/MAM/N{degree sign}325/14)
This publication has 42 references indexed in Scilit:
- An innovative tool for moving malaria PCR detection of parasite reservoir into the fieldMalaria Journal, 2013
- Male and Female Plasmodium falciparum Mature Gametocytes Show Different Responses to Antimalarial DrugsAntimicrobial Agents and Chemotherapy, 2013
- G6PD deficiency in Plasmodium falciparum and Plasmodium vivax malaria-infected Cambodian patientsMalaria Journal, 2013
- Predicting mosquito infection from Plasmodium falciparum gametocyte density and estimating the reservoir of infectioneLife, 2013
- Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trialThe Lancet Infectious Diseases, 2010
- Heritability of the Human Infectious Reservoir of Malaria ParasitesPLOS ONE, 2010
- Dihydroartemisinin-Piperaquine and Artemether-Lumefantrine for Treating Uncomplicated Malaria in African Children: A Randomised, Non-Inferiority TrialPLOS ONE, 2009
- Artemisinin Resistance inPlasmodium falciparumMalariaThe New England Journal of Medicine, 2009
- Artemisinin-based combination therapy for treating uncomplicated malariaEmergencias, 2009
- Evidence of Artemisinin-Resistant Malaria in Western CambodiaThe New England Journal of Medicine, 2008